{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:44:39Z","timestamp":1772005479205,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.semdp.2023.04.001","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T15:57:16Z","timestamp":1680710236000},"page":"182-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Updates in molecular genetics of therapy-related myeloid neoplasms"],"prefix":"10.1053","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-4569","authenticated-orcid":false,"given":"Miguel Dario","family":"Cantu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semdp.2023.04.001_bib0001","unstructured":"Swerdlow S.H., Campo E., Harris N.L., et\u00a0al., WHO classification of tumours of haematopoietic and lymphoid tissues, 2016."},{"key":"10.1053\/j.semdp.2023.04.001_bib0002","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","author":"Morton","year":"2013","journal-title":"Blood"},{"issue":"318","key":"10.1053\/j.semdp.2023.04.001_bib0003","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0004","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group, Blood","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Hulegardh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0006","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.2004.99.301","article-title":"Prognosis in therapy-related acute myeloid leukemia and impact of karyotype","volume":"22","author":"Kern","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0007","series-title":"Acute Myeloid Leukemia: The Good, the Bad, and the Ugly","first-page":"555","author":"Kuykendall","year":"2018"},{"key":"10.1053\/j.semdp.2023.04.001_bib0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series, Blood","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0009","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/asheducation.V2016.1.24.088333","article-title":"Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?, Hematology","author":"Heuser","year":"2016","journal-title":"Am Soc Hematol Educ Program"},{"key":"10.1053\/j.semdp.2023.04.001_bib0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"The Role of TP53 Mutations in the origin and evolution of therapy-related AML","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1053\/j.semdp.2023.04.001_bib0011","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell, Cell Press"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.001_bib0012","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1053\/j.semdp.2023.04.001_bib0013","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1309\/NQ3PMV4U8YV39JWJ","article-title":"Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant, American journal of clinical pathology","author":"Singh","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0014","first-page":"2137","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","author":"Kayser","year":"2011","journal-title":"Blood Content Repository Only!"},{"key":"10.1053\/j.semdp.2023.04.001_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2010.01464.x","article-title":"Reasons for treating secondary AML as de novo AML","author":"\u00d8stgrd","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0016","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0017","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pathol.2022.03.002","article-title":"Panel-based gene testing in myelodysplastic\/myeloproliferative neoplasm overlap syndromes: australasian Leukaemia and Lymphoma Group (ALLG) consensus statement","volume":"54","author":"Enjeti","year":"2022","journal-title":"Pathology"},{"key":"10.1053\/j.semdp.2023.04.001_bib0019","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41375-019-0479-8","article-title":"The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution","volume":"33","author":"Singhal","year":"2019","journal-title":"Leukemia"},{"key":"10.1053\/j.semdp.2023.04.001_bib0020","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25104","article-title":"Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0021","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semdp.2023.04.001_bib0022","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0023","first-page":"1703","volume":"36","author":"Khoury","year":"2022"},{"key":"10.1053\/j.semdp.2023.04.001_bib0024","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","article-title":"Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification\u2014An approach to classification of patients with t-MDS","volume":"35","author":"Kuendgen","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.semdp.2023.04.001_bib0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0026","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.7150\/jca.32475","article-title":"Glioblastoma treatment modalities besides surgery","volume":"10","author":"Zhang","year":"2019","journal-title":"J Cancer"},{"key":"10.1053\/j.semdp.2023.04.001_bib0027","first-page":"204","article-title":"Influence of DNA damage and repair upon the risk of treatment related leukemia","author":"Guillem","year":"2009","journal-title":"Taylor & Francis"},{"key":"10.1053\/j.semdp.2023.04.001_bib0028","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1200\/JCO.2011.38.7340","article-title":"Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms","author":"Nardi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0029","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/ijerph9062075","article-title":"Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents","author":"Cowell","year":"2012","journal-title":"Int J Environ Res Public Health"},{"key":"10.1053\/j.semdp.2023.04.001_bib0030","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1182\/blood-2008-10-183244","article-title":"Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility, Blood","author":"Knight","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0031","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood.V86.9.3542.bloodjournal8693542","article-title":"Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia, Blood","author":"Pedersen-Bjergaard","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0032","first-page":"1367","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, Blood","author":"RC","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0033","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2013-03-491399","article-title":"Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0034","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamaoncol.2015.6053","article-title":"Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma","volume":"2","author":"Swisher","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0035","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1053\/j.semdp.2023.04.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML, Blood advances","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.semdp.2023.04.001_bib0037","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0038","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0039","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.semdp.2023.04.001_bib0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-017-3143-2","article-title":"Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor","volume":"97","author":"Terada","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0041","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"key":"10.1053\/j.semdp.2023.04.001_bib0042","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.001_bib0043","first-page":"1","article-title":"Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a bone marrow pathology group study","author":"Rogers","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0044","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1309\/AJCP5ETHDXO6NCGZ","article-title":"Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome","volume":"131","author":"Gustafson","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0045","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/leu.2014.4","article-title":"High number of additional genetic lesions in acute myeloid leukemia with t(8;21)\/RUNX1-RUNX1T1: frequency and impact on clinical outcome","volume":"28","author":"Krauth","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.semdp.2023.04.001_bib0046","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/cncr.24367","article-title":"Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia","volume":"115","author":"Borthakur","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.semdp.2023.04.001_bib0047","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/gcc.10043","article-title":"Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an International Workshop","volume":"33","author":"Andersen","year":"2002","journal-title":"Genes Chromos Cancer"},{"key":"10.1053\/j.semdp.2023.04.001_bib0048","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00400","article-title":"Clinicopathologic and Molecular analysis of normal karyotype therapy-related and de novo acute myeloid leukemia: a multi-institutional study by the bone marrow pathology group","author":"Cantu","year":"2023","journal-title":"JCO Precision Oncol"},{"issue":"5","key":"10.1053\/j.semdp.2023.04.001_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0316-3","article-title":"Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype","volume":"10","author":"Samra","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.semdp.2023.04.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18154","article-title":"Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype","author":"Tariq","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0051","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2007.06613.x","article-title":"Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia","volume":"137","author":"Seedhouse","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.001_bib0052","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/13.S1.34","article-title":"Children's Oncology G: polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications","volume":"13","author":"Kelly","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semdp.2023.04.001_bib0053","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/sj.onc.1209208","article-title":"Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia","volume":"25","author":"Worrillow","year":"2006","journal-title":"Oncogene"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257023000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257023000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:24:03Z","timestamp":1760037843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257023000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0740257023000308"],"URL":"https:\/\/doi.org\/10.1053\/j.semdp.2023.04.001","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in molecular genetics of therapy-related myeloid neoplasms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semdp.2023.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}